<p><em>– 融资包括领先的美国生物技术机构投资者和共同基金 –</em></p>
<p>洛杉矶，CA，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Immix Biopharma, Inc.（“ImmixBio”，“公司”，“我们” 或 “我们” 或 “IMMX”），全球复发/难治性 AL 淀粉样变的领导者，今天宣布完成其之前宣布的承销注册发行，共计 19,117,646 股普通股，公众发行价格为每股 5.10 美元，并向某些投资者提供 490,196 股普通股的预融资认股权证，公众发行价格为每个预融资认股权证 5.09 美元，这代表了普通股的每股公开发行价格，减去每个预融资认股权证的 0.01 美元行使价格。扣除承销折扣、佣金和其他发行费用后，Immix 从此次发行中获得的净收益约为 9370 万美元。</p>
<p>融资包括领先的美国生物技术机构投资者和共同基金。</p>
<p>摩根士丹利担任此次发行的唯一账簿管理人。Citizens Capital Markets 和瑞穗银行担任此次发行的共同管理人。</p>
<p>注册发行的证券是根据美国证券交易委员会（“SEC”）于 2023 年 1 月 3 日提交的 S-3 表格（文件编号 333-269100）下的 “货架” 注册声明进行发行和销售的，该注册声明于 2023 年 1 月 11 日生效。描述注册发行条款的招股说明书补充及相关招股说明书已向 SEC 提交，并可在其网站 www.sec.gov 上获取。有关此次发行的招股说明书补充及相关招股说明书的副本也可以从摩根士丹利公司（Morgan Stanley &amp; Co. LLC）获取，地址：纽约市 Varick 街 180 号，二楼，邮政编码 10014，电话：1-866-718-1649 或电子邮件：prospectus@morganstanley.com。</p>
<p>本新闻稿不构成出售或招揽购买本文所述任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，若该要约、招揽或销售在任何此类州或司法管辖区的证券法下是非法的，须在注册或资格之前进行。</p>
<p><strong>关于 Immix Biopharma, Inc.</strong></p>
<p>Immix Biopharma, Inc.（ImmixBio）（纳斯达克：IMMX）是全球复发/难治性 AL 淀粉样变的领导者。AL 淀粉样变是一种毁灭性的疾病，免疫系统本应保护，但却产生有毒的轻链，堵塞心脏、肾脏和肝脏，导致器官衰竭和死亡。我们的主要候选药物是立体优化的 BCMA 靶向嵌合抗原受体 T 细胞疗法 NXC-201，具有 “数字过滤器”，旨在过滤掉非特异性激活。NXC-201 教会免疫系统识别并消除有毒轻链的来源。NXC-201 正在美国多中心研究中评估，针对复发/难治性 AL 淀粉样变的 NEXICART-2（NCT06097832），具有注册设计。NXC-201 已获得美国 FDA 的再生医学先进疗法（RMAT）认证和 FDA 及欧盟 EMA 的孤儿药资格（ODD）。</p>
<p><strong>联系方式</strong></p>
<p>Mike Moyer</p>
<p>LifeSci Advisors</p>
<p>mmoyer@lifesciadvisors.com</p>
<p><strong>公司联系方式</strong> Gabriel Morris, CFOirteam@immixbio.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTROaU0zTXpFME5qSXhJelV3TURBNU9ERXdOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTROaU0zTXpFME5qSXhJelV3TURBNU9ERXdOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDJjZGYwMmEtOTAwMS00Y2MwLWI3NTItYmJkN2YyY2ExN2MwLTUwMDA5ODEwNC0yMDI1LTEyLTA5LWVu/tiny/Immix-Biopharma-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDJjZGYwMmEtOTAwMS00Y2MwLWI3NTItYmJkN2YyY2ExN2MwLTUwMDA5ODEwNC0yMDI1LTEyLTA5LWVu/tiny/Immix-Biopharma-Inc-.png"/></p>

IMMX

<p>Immix Biopharma 宣布完成了一项 1 亿美元的承销普通股和预先融资认股权证的发行，扣除费用后筹集了约 9370 万美元。此次发行包括了领先的美国生物技术机构投资者和共同基金。摩根士丹利担任唯一的账簿管理经理，Citizens Capital Markets 和瑞穗银行担任共同经理。此次发行是在向美国证券交易委员会（SEC）提交的架构注册声明下进行的。Immix Biopharma 是复发/难治性 AL 淀粉样变病治疗的领导者</p>

<p><em>– Financing includes leading U.S. biotechnology institutional investors and mutual funds –</em></p>
<div class="lb-trans"><p><em>– 融资包括领先的美国生物技术机构投资者和共同基金 –</em></p>
</div><p>LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ” IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $93.7 million.</p>
<div class="lb-trans"><p>洛杉矶，CA，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Immix Biopharma, Inc.（“ImmixBio”，“公司”，“我们” 或 “我们” 或 “IMMX”），全球复发/难治性 AL 淀粉样变的领导者，今天宣布完成其之前宣布的承销注册发行，共计 19,117,646 股普通股，公众发行价格为每股 5.10 美元，并向某些投资者提供 490,196 股普通股的预融资认股权证，公众发行价格为每个预融资认股权证 5.09 美元，这代表了普通股的每股公开发行价格，减去每个预融资认股权证的 0.01 美元行使价格。扣除承销折扣、佣金和其他发行费用后，Immix 从此次发行中获得的净收益约为 9370 万美元。</p>
</div><p>The financing includes leading U.S. biotechnology institutional investors and mutual funds.</p>
<div class="lb-trans"><p>融资包括领先的美国生物技术机构投资者和共同基金。</p>
</div><p>Morgan Stanley acted as the sole book-running manager for the offering. Citizens Capital Markets and Mizuho acted as co-managers for the offering.</p>
<div class="lb-trans"><p>摩根士丹利担任此次发行的唯一账簿管理人。Citizens Capital Markets 和瑞穗银行担任此次发行的共同管理人。</p>
</div><p>The securities in the registered offering were offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-269100), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 3, 2023, and declared effective on January 11, 2023. A prospectus supplement and accompanying prospectus describing the terms of the registered offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley &amp; Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: prospectus@morganstanley.com.</p>
<div class="lb-trans"><p>注册发行的证券是根据美国证券交易委员会（“SEC”）于 2023 年 1 月 3 日提交的 S-3 表格（文件编号 333-269100）下的 “货架” 注册声明进行发行和销售的，该注册声明于 2023 年 1 月 11 日生效。描述注册发行条款的招股说明书补充及相关招股说明书已向 SEC 提交，并可在其网站 www.sec.gov 上获取。有关此次发行的招股说明书补充及相关招股说明书的副本也可以从摩根士丹利公司（Morgan Stanley &amp; Co. LLC）获取，地址：纽约市 Varick 街 180 号，二楼，邮政编码 10014，电话：1-866-718-1649 或电子邮件：prospectus@morganstanley.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买本文所述任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，若该要约、招揽或销售在任何此类州或司法管辖区的证券法下是非法的，须在注册或资格之前进行。</p>
</div><p><strong>About Immix Biopharma, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Immix Biopharma, Inc.</strong></p>
</div><p>Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.</p>
<div class="lb-trans"><p>Immix Biopharma, Inc.（ImmixBio）（纳斯达克：IMMX）是全球复发/难治性 AL 淀粉样变的领导者。AL 淀粉样变是一种毁灭性的疾病，免疫系统本应保护，但却产生有毒的轻链，堵塞心脏、肾脏和肝脏，导致器官衰竭和死亡。我们的主要候选药物是立体优化的 BCMA 靶向嵌合抗原受体 T 细胞疗法 NXC-201，具有 “数字过滤器”，旨在过滤掉非特异性激活。NXC-201 教会免疫系统识别并消除有毒轻链的来源。NXC-201 正在美国多中心研究中评估，针对复发/难治性 AL 淀粉样变的 NEXICART-2（NCT06097832），具有注册设计。NXC-201 已获得美国 FDA 的再生医学先进疗法（RMAT）认证和 FDA 及欧盟 EMA 的孤儿药资格（ODD）。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Mike Moyer</p>
<div class="lb-trans"><p>Mike Moyer</p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>mmoyer@lifesciadvisors.com</p>
<div class="lb-trans"><p>mmoyer@lifesciadvisors.com</p>
</div><p><strong>Company Contact</strong> Gabriel Morris, CFOirteam@immixbio.com</p>
<div class="lb-trans"><p><strong>公司联系方式</strong> Gabriel Morris, CFOirteam@immixbio.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTROaU0zTXpFME5qSXhJelV3TURBNU9ERXdOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTY4NiM3MzE0NjIxIzUwMDA5ODEwNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDJjZGYwMmEtOTAwMS00Y2MwLWI3NTItYmJkN2YyY2ExN2MwLTUwMDA5ODEwNC0yMDI1LTEyLTA5LWVu/tiny/Immix-Biopharma-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NDJjZGYwMmEtOTAwMS00Y2MwLWI3NTItYmJkN2YyY2ExN2MwLTUwMDA5ODEwNC0yMDI1LTEyLTA5LWVu/tiny/Immix-Biopharma-Inc-.png"/></p>

Immix Biopharma 宣布完成扩大规模的 1 亿美元普通股和预付认股权证的承销发行 | IMMX 股票新闻